BASF and Biomillenia join forces in microbiome research
BASF and Biomillenia announced the signing of a microbiome discovery agreement. The collaboration aims to identify novel dermocosmetic active ingredients involved in promoting skin health.

Bacteria in droplets generated by the lap-on-a-chip-technology.
© Biomillenia
The French company Biomillenia will contribute its unique microbiome-on-a-chip technology that has the ability to grow specific microbes and maintain a higher diversity of living microbes than with standard microbiology methods. It will allow BASF to explore how active ingredients can modulate the presence and growth of the skin microbiota, and consequently affect its health.
By bringing together interdisciplinary know-how from within the company as well as from external partners, BASF constantly expands its activities dedicated to developing solutions acting on or through the skin microbiota.
“The skin hosts a huge and varied microbiota and as such plays an important role in skin health. Biomillenia’s ability to rapidly identify novel microbes and screen for active ingredients involved in promoting healthy skin will enable new research possibilities and market opportunities for BASF,” said David Hérault, R&D Global Director of BASF Beauty Care Solutions.
“The microbiome is a vast natural pool of mostly undiscovered microbes that can be leveraged across several industries, including consumer health, agriculture, animal health and food. We are supporting companies in these sectors by providing access to our technology platform to culture and perform functional analysis of microbes in low volume droplets using proprietary lab-on-a-chip technology. In addition, our customers can gain access to our microbial culture collection and state of the art microbe isolation and sequencing technologies,” said Dirk Loeffert, Ph.D., CEO of Biomillenia.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents

Impressive results against autoimmune disease - Severe systemic lupus no longer detectable after cancer medication treatment
Scientists identify a candidate gene for osteoporosis - Gene may underlie differences between African Americans and Caucasians

Cycling between a healthy and unhealthy diet has significant health effect - Diet cycling impacts spatial memory: rat study
Institute of Clinical Research (ICR) - Bourne End, Buckinghamshire, United Kingdom
Category:Metabolism_literature
Deutsche Atemwegsliga e.V. - Bad Lippspringe, Germany
List_of_drugs:_Pf-Ph

Several baffling puzzles in protein molecular structure solved with new method - Determining the molecular configuration of proteins is important in nanotechology, drug design, disease research and many other fields
American Peptide Company expands its manufacturing and service portfolio
